Platelet glycoprotein Ibα is an important mediator of ischemic stroke in mice

Experimental and Translational Stroke Medicine

Volumn 3, Issue 1, 2011, Pages

  De Meyer, Simon F ^a,b,c,d   Schwarz, Tobias ^e   Schatzberg, Daphne ^a,b   Wagner, Denisa D ^a,b,c  

^a CENTER FOR BLOOD RESEARCH   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN IB ALPHA; INTERLEUKIN 4 RECEPTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD VESSEL; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 80053163066     PISSN: None     EISSN: 20407378     Source Type: Journal    
DOI: 10.1186/2040-7378-3-9     Document Type: Article

References (27)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367:1747-1757. 10.1016/S0140-6736(06)68770-9, 16731270.
2. Andrews RK, Gardiner EE, Shen Y, Whisstock JC, Berndt MC. Glycoprotein Ib-IX-V. Int J Biochem Cell Biol 2003, 35:1170-1174. 10.1016/S1357-2725(02)00280-7, 12757754.
3. Salles II, Feys HB, Iserbyt BF, De Meyer SF, Vanhoorelbeke K, Deckmyn H. Inherited traits affecting platelet function. Blood Rev 2008, 22:155-172. 10.1016/j.blre.2007.11.002, 18180086.
4. De Meyer SF, Deckmyn H, Vanhoorelbeke K. von Willebrand factor to the rescue. Blood 2009, 113:5049-5057. 10.1182/blood-2008-10-165621, 19318682.
5. Bergmeier W, Piffath CL, Goerge T, Cifuni SM, Ruggeri ZM, Ware J, Wagner DD. The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc Natl Acad Sci USA 2006, 103:16900-16905. 10.1073/pnas.0608207103, 1636551, 17075060.
6. Kanaji T, Russell S, Ware J. Amelioration of the macrothrombocytopenia associated with the murine Bernard-Soulier syndrome. Blood 2002, 100:2102-2107. 10.1182/blood-2002-03-0997, 12200373.
7. Murakami K, Kondo T, Epstein CJ, Chan PH. Overexpression of CuZn-superoxide dismutase reduces hippocampal injury after global ischemia in transgenic mice. Stroke 1997, 28:1797-1804. 10.1161/01.STR.28.9.1797, 9303028.
8. Kleinschnitz C, De Meyer SF, Schwarz T, Austinat M, Vanhoorelbeke K, Nieswandt B, Deckmyn H, Stoll G. Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood 2009, 113:3600-3603. 10.1182/blood-2008-09-180695, 19182208.
9. De Meyer SF, Schwarz T, Deckmyn H, Denis CV, Nieswandt B, Stoll G, Vanhoorelbeke K, Kleinschnitz C. Binding of von Willebrand Factor to Collagen and Glycoprotein Ibalpha, But Not to Glycoprotein IIb/IIIa, Contributes to Ischemic Stroke in Mice. Arterioscler Thromb Vasc Biol 2010, 30:1949-1951. 10.1161/ATVBAHA.110.208918, 20616311.
10. Clark WM, Lessov NS, Dixon MP, Eckenstein F. Monofilament intraluminal middle cerebral artery occlusion in the mouse. Neurol Res 1997, 19:641-648.
11. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986, 17:472-476. 10.1161/01.STR.17.3.472, 3715945.
12. Stoll G, Kleinschnitz C, Nieswandt B. Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood 2008, 112:3555-3562. 10.1182/blood-2008-04-144758, 18676880.
13. Stoll G, Kleinschnitz C, Nieswandt B. The role of glycoprotein Ibalpha and von Willebrand factor interaction in stroke development. Hämostaseologie 2010, 30:136-138.
14. Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 2007, 115:2323-2330. 10.1161/CIRCULATIONAHA.107.691279, 17438148.
15. Zhao B-Q, Chauhan AK, Canault M, Patten IS, Yang JJ, Dockal M, Scheiflinger F, Wagner DD. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood 2009, 114:3329-3334. 10.1182/blood-2009-03-213264, 2759655, 19687510.
16. Baker RI, Eikelboom J, Lofthouse E, Staples N, Afshar-Kharghan V, López JA, Shen Y, Berndt MC, Hankey G. Platelet glycoprotein Ibalpha Kozak polymorphism is associated with an increased risk of ischemic stroke. Blood 2001, 98:36-40. 10.1182/blood.V98.1.36, 11418460.
17. Reiner AP, Kumar PN, Schwartz SM, Longstreth WT, Pearce RM, Rosendaal FR, Psaty BM, Siscovick DS. Genetic variants of platelet glycoprotein receptors and risk of stroke in young women. Stroke 2000, 31:1628-1633. 10.1161/01.STR.31.7.1628, 10884464.
18. Bongers TN, de Maat MPM, van Goor M-LPJ, Bhagwanbali V, van Vliet HHDM, Gómez García EB, Dippel DWJ, Leebeek FWG. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 2006, 37:2672-2677. 10.1161/01.STR.0000244767.39962.f7, 16990571.
19. Wieberdink RG, van Schie MC, Koudstaal PJ, Hofman A, Witteman JCM, de Maat MPM, Leebeek FWG, Breteler MMB. High von Willebrand Factor Levels Increase the Risk of Stroke. The Rotterdam Study. Stroke 2010, 41:2151-2156. 10.1161/STROKEAHA.110.586289, 20798373.
20. De Meyer SF, Vandeputte N, Pareyn I, Petrus I, Lenting PJ, Chuah MKL, VandenDriessche T, Deckmyn H, Vanhoorelbeke K. Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease. Arterioscler Thromb Vasc Biol 2008, 28:1621-1626. 10.1161/ATVBAHA.108.168369, 18556568.
21. Denis C, Methia N, Frenette PS, Rayburn H, Ullman-Culleré M, Hynes RO, Wagner DD. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci USA 1998, 95:9524-9529. 10.1073/pnas.95.16.9524, 21371, 9689113.
22. De Meyer SF, De Maeyer B, Deckmyn H, Vanhoorelbeke K. Von Willebrand factor: drug and drug target. Cardiovasc Hematol Disord Drug Targets 2009, 9:9-20. 10.2174/187152909787581327, 19275573.
23. De Meyer SF, Vanhoorelbeke K, Ulrichts H, Staelens S, Feys HB, Salles I, Fontayne A, Deckmyn H. Development of monoclonal antibodies that inhibit platelet adhesion or aggregation as potential anti-thrombotic drugs. Cardiovasc Hematol Disord Drug Targets 2006, 6:191-207. 10.2174/187152906778249536, 17017902.
24. Vanhoorelbeke K, Ulrichts H, Van de Walle G, Fontayne A, Deckmyn H. Inhibition of platelet glycoprotein Ib and its antithrombotic potential. Curr Pharm Des 2007, 13:2684-2697. 10.2174/138161207781662867, 17897012.
25. Stoll G, Kleinschnitz C, Nieswandt B. Combating innate inflammation: a new paradigm for acute treatment of stroke?. Ann N Y Acad Sci 2010, 1207:149-154. 10.1111/j.1749-6632.2010.05730.x, 20955438.
26. Hankey GJ, Eikelboom JW. Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Lancet Neurol 2010, 9:273-284. 10.1016/S1474-4422(10)70038-7, 20170841.
27. Markus HS, McCollum C, Imray C, Goulder MA, Gilbert J, King A. The von Willebrand Inhibitor ARC1779 Reduces Cerebral Embolization After Carotid Endarterectomy: A Randomized Trial. Stroke 2011, 42:2149-2153. 10.1161/STROKEAHA.111.616649, 21700934.